Patents
Literature
4 results about "Antiangiogenesis Therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels.
Methods for selection of cancer patients for Anti-angiogenic and immune checkpoint blockage therapies and combinations thereof
PendingUS20260112450A1Organic active ingredientsDrug and medicationsAntiangiogenesis TherapyOncology
The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., ICB therapy and / or anti-angiogenic) in subjects having a cancer or tumor based on angio-immune panel signatures. The methods may further comprise identifying suitable treatment for the subject based on the angio-immune panel.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Amorphous form of cabozantinib sulfate monohydrate and method of preparation
PCT designated stageWO2026142524A1Antiangiogenesis TherapyMedullary carcinoma thyroid
The present invention refers to an amorphous form of cabozantinib sulphate monohydrate and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.
Owner:DEVA HLDG
Novel polymorph of cabozantinib hemifumarate sesquihydrate (form a), cabozantinib hemifumarate hemipentahydrate (form b) and method of preparation
PCT designated stageWO2026142527A1Antiangiogenesis TherapyMedullary carcinoma thyroid
The present invention refers to a novel crystalline polymorphic form of cabozantinib hemifumarate sesquihydrate designated as Form A, a novel crystalline polymorphic form of cabozantinib hemifumarate hemipentahydrate designated as Form B and a process for their preparation, a pharmaceutical composition comprising Form A or Form B, and their use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.
Owner:DEVA HLDG
Novel polymorph of cabozantinib HEMI-(s)-malate (form a) and method of preparation
PCT designated stageWO2026142525A1Antiangiogenesis TherapyAntiangiogenic therapy
The present invention refers to a crystalline form of cabozantinib hemi-(S)-malate designated as Form A and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.
Owner:DEVA HLDG